NasdaqGS:VRTXBiotechs
Is Vertex Pharmaceuticals (VRTX) Cheap On Its AbCellera Collaboration News?
Vertex Pharmaceuticals stock reaction to new AbCellera collaboration
Vertex Pharmaceuticals (VRTX) drew fresh attention after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers for autoimmune diseases. Under the agreement, Vertex will fund research and retain rights to advance and commercialize the resulting therapies.
See our latest analysis for Vertex Pharmaceuticals.
For context, Vertex Pharmaceuticals shares are at US$483.33, with a 90 day share price...